MA
WST icon

MJP Associates’s West Pharmaceutical WST Stock Holding History

MJP Associates’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,368
Closed -$376K – 274
2025
Q4 		$376K Sell
1,368
-262
-16% -$71.7K 0.05% 163
2025
Q3 		$428K Sell
1,630
-340
-17% -$82.6K 0.06% 150
2025
Q2 		$431K Buy
1,970
+52
+3% +$11.1K 0.06% 136
2025
Q1 		$429K Buy
1,918
+396
+26% +$109K 0.08% 130
2024
Q4 		$499K Buy
1,522
+87
+6% +$27.4K 0.09% 109
2024
Q3 		$431K Sell
1,435
-60
-4% -$18.4K 0.08% 129
2024
Q2 		$492K Buy
1,495
+233
+18% +$82.3K 0.1% 103
2024
Q1 		$499K Buy
1,262
+383
+44% +$142K 0.11% 105
2023
Q4 		$309K Buy
879
+133
+18% +$47.1K 0.08% 126
2023
Q3 		$280K Buy
746
+171
+30% +$66.1K 0.08% 112
2023
Q2 		$220K Buy
+575
New +$205K 0.07% 137
2022
Q1 		– Sell
-611
Closed -$272K – 177
2021
Q4 		$272K Buy
611
+104
+21% +$44.8K 0.08% 120
2021
Q3 		$215K Buy
+507
New +$214K 0.07% 131

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MJP Associates's WST Position: Q1 2026 in Review

MJP Associates sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 1,368 shares — an estimated $376K sold.

MJP Associates first reported a position in WST in Q3 2021 and held it in 13 quarters. The position peaked at $499K in Q1 2024. 755 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • MJP Associates reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • MJP Associates sold 1,368 West Pharmaceutical shares in Q1 2026, an estimated $376K.
  • MJP Associates first reported a position in West Pharmaceutical in Q3 2021 and held it in 13 quarters.
  • MJP Associates's West Pharmaceutical position peaked at $499K in Q1 2024.
  • 755 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on MJP Associates's 13F filing for Q1 2026, filed 5 May 2026.